Details of Disease

General Information of Disease (ID: DISZ44JH)

• Disease Name: Gram-positive bacterial infection
• Synonyms: infection, Gram-positive bacterial; Gram Positive bacterial infections; infections, Gram-positive bacterial; Gram-positive bacterial infection; bacterial infections, Gram Positive; bacterial infection, Gram-positive; infections, Gram Positive bacterial; bacterial infections, Gramme Positive; bacterial infections, Gram-positive; infections, Gramme Positive bacterial; Gramme Positive bacterial infections
• Disease Class: 1B74-1F40: Gram-positive bacterial infection
• Definition: Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.|Editor note: this does not correspond to a taxonomic grouping, so classification is manual for now
• Disease Hierarchy:
  DIS5QJ9S: Bacterial infection
  DISZ44JH: Gram-positive bacterial infection
• ICD Code:
  ICD-11: ICD-11: 1B74-1G40
  Expand ICD-9: 1.00E+183
• Disease Identifiers:
  MONDO ID: MONDO_0021679
  MESH ID: D016908
  UMLS CUI: C0085426
  MedGen ID: 39283

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Balofloxacin	DMPWNDB	Approved	Small molecular drug	[1]
Cefozopran	DMKBTFG	Approved	Small molecular drug	[1]
Ciprofloxacin XR	DM2NLS9	Approved	Small molecular drug	[1]
Doripenem	DM9UCJK	Approved	Small molecular drug	[1]
Faropenem	DMX7A5V	Approved	Small molecular drug	[1]
Lincomycin	DMVTHER	Approved	Small molecular drug	[2]
Oritavancin	DM28D05	Approved	Small molecular drug	[3]

This Disease is Treated as An Indication in 4 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
TD-1792	DMGKBZH	Phase 3	Small molecular drug	[4]
Oxazolidinones	DMBM47Z	Phase 2	Small molecular drug	[5]
SUN13834	DMPK34E	Phase 2	Small molecular drug	[1]
TD-1607	DMV2QLM	Phase 1	NA	[6]

This Disease is Treated as An Indication in 4 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cephaloridine	DM4Y95F	Withdrawn from market	Small molecular drug	[7]
DA-7101	DMHSLVO	Discontinued in Phase 3	NA	[1]
MC-02331	DMJ1PU1	Terminated	NA	[10]
THF carbapenems	DM9J662	Terminated	NA	[11]

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BAL-0019764	DMD1KGV	Preclinical	NA	[8]
NVB-333	DMBFR6O	Preclinical	NA	[9]

This Disease is Treated as An Indication in 26 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ABI-200	DMNB2N3	Investigative	NA	[12]
AM-3005	DMA33PB	Investigative	NA	[12]
B-4474	DMDK9TL	Investigative	Small molecular drug	[12]
BSP-C728	DMFDJU3	Investigative	NA	[12]
BSP-C801	DMA2ZQN	Investigative	NA	[12]
DAV-147	DMZNGDO	Investigative	NA	[12]
HKI-9924129	DM5LR2B	Investigative	Small molecular drug	[1]
LED-209	DMMOIIP	Investigative	NA	[12]
MBI-2401	DM5X9IZ	Investigative	Small molecular drug	[12]
MGB-101	DMIL46S	Investigative	NA	[12]
MT-061	DMDK6BP	Investigative	NA	[13]
NB3178	DMNM6GQ	Investigative	NA	[1]
NB3322	DMJHWGS	Investigative	NA	[1]
NPI-3114	DM32QU6	Investigative	NA	[12]
NPI-3304	DMLR2I8	Investigative	NA	[12]
NZ-17000	DM4H723	Investigative	NA	[12]
Pleuromutilins	DMYQXYN	Investigative	NA	[12]
Polymyxins	DM7RPHN	Investigative	NA	[12]
PT4.0	DMH6654	Investigative	NA	[12]
Ro 5-4864	DMTQP0K	Investigative	Small molecular drug	[1]
RWJ-140998	DMP7SI9	Investigative	Small molecular drug	[1]
RWJ-3981	DMBVLCQ	Investigative	Small molecular drug	[1]
SLP-0906	DML3WSM	Investigative	NA	[12]
SLP-1004	DMGBJ63	Investigative	NA	[12]
Tripropeptin C	DMCPK7D	Investigative	NA	[12]
YJP-40101	DMESW2E	Investigative	NA	[12]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 1 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
MARS1	DE0K52I	Strong	Biomarker	[14]

This Disease Is Related to 4 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
NLRP6	OTEREN4W	Disputed	Biomarker	[15]
RNASE3	OTVE2XD1	moderate	Therapeutic	[16]
IQSEC2	OTYFRM4Q	Strong	Biomarker	[17]
PGLYRP1	OTBTPR2T	Strong	Biomarker	[18]

References

• [1] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [2] FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 050317.
• [3] How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
• [4] ClinicalTrials.gov (NCT00442832) TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection. U.S. National Institutes of Health.
• [5] ClinicalTrials.gov (NCT00646958) Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections. U.S. National Institutes of Health.
• [6] ClinicalTrials.gov (NCT01949103) TD-1607 MAD Study in Healthy Subjects. U.S. National Institutes of Health.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [8] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800016545)
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030484)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007651)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013152)
• [12] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2608).
• [14] Development of Methionyl-tRNA Synthetase Inhibitors as Antibiotics for Gram-Positive Bacterial Infections.Antimicrob Agents Chemother. 2017 Oct 24;61(11):e00999-17. doi: 10.1128/AAC.00999-17. Print 2017 Nov.
• [15] NLRP6 negatively regulates pulmonary host defense in Gram-positive bacterial infection through modulating neutrophil recruitment and function.PLoS Pathog. 2018 Sep 24;14(9):e1007308. doi: 10.1371/journal.ppat.1007308. eCollection 2018 Sep.
• [16] Refining the eosinophil cationic protein antibacterial pharmacophore by rational structure minimization.J Med Chem. 2011 Jul 28;54(14):5237-44. doi: 10.1021/jm200701g. Epub 2011 Jul 1.
• [17] Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02181-16. doi: 10.1128/AAC.02181-16. Print 2017 Apr.
• [18] Molecular characteristics of hemoglobins in blood clam and their immune responses to bacterial infection.Int J Biol Macromol. 2017 Jun;99:375-383. doi: 10.1016/j.ijbiomac.2017.02.078. Epub 2017 Feb 24.